Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 12, 2012 - Issue 12
Submit an article Journal homepage
146
Views
19
CrossRef citations to date
0
Altmetric
Review

Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition

Michael Gnant Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, A-1090 Wien, Waehringer Guertel 18–20, Austria. [email protected]
Pages 1579-1589 | Published online: 10 Jan 2014

References

  • Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J. Steroid Biochem. Mol. Biol. 125(1–2), 13–22 (2011).
  • Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21(11), 2101–2109 (2003).
  • Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr. Relat. Cancer 13(Suppl. 1), S15–S24 (2006).
  • Landsman-Blumberg P, Namjoshi M, Thomson E, Johnson W. Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2- breast cancer. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2012 (Abstract 593).
  • Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 15(5), 584–594 (2006).
  • Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 65(12), 5380–5389 (2005).
  • Shi L, Dong B, Li Z et al. Expression of ER-{α}36, a novel variant of estrogen receptor {α}, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 27(21), 3423–3429 (2009).
  • Sabnis GJ, Jelovac D, Long BJ, Schayowitz A, Belosay A, Brodie AMH. Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole. Presented at: 97th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 1–5 April 2006 (Abstract 2316).
  • Schiff R, Reddy P, Ahotupa M et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl Cancer Inst. 92(23), 1926–1934 (2000).
  • Zhou Y, Yau C, Gray JW et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7, 59 (2007).
  • Chen D, Washbrook E, Sarwar N et al. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32), 4921–4931 (2002).
  • Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241), 1491–1494 (1995).
  • Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276(13), 9817–9824 (2001).
  • Miller TW, Hennessy BT, González-Angulo AM et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest. 120(7), 2406–2413 (2010).
  • Santen RJ, Song RX, Zhang Z et al. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J. Steroid Biochem. Mol. Biol. 95(1–5), 155–165 (2005).
  • Tokunaga E, Kimura Y, Mashino K et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13(2), 137–144 (2006).
  • Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 106(1–5), 102–110 (2007).
  • Bergh J, Jönsson PE, Lidbrink EK et al. FACT: an open-label randomized Phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J. Clin. Oncol. 30(16), 1919–1925 (2012).
  • Dodwell D, Coombes G, Bliss JM, Kilburn LS, Johnston S; SoFEA Trial Management Group. Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial. Clin. Oncol. (R. Coll. Radiol.) 20(5), 321–324 (2008).
  • Johnston S, Kilburn LS, Ellis P et al. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non-steroidal aromatase inhibitor: first results of the SoFEa trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). Presented at: 8th European Breast Cancer Conference (EBCC). Vienna, Austria, 21–24 March 2012 (Abstract 2LBA)
  • Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N. Engl. J. Med. 367(5), 435–444 (2012).
  • Afinitor (everolimus), prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2012).
  • Rapamune (sirolimus), prescribing information. Wyeth Pharmaceuticals Inc., a division of Pfizer Inc., Philadelphia, PA, USA (2011).
  • Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int. J. Clin. Exp. Pathol. 4(5), 476–495 (2011).
  • Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124(3), 471–484 (2006).
  • Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol. Cell. Biol. 32(1), 2–11 (2012).
  • Murakami M, Ichisaka T, Maeda M et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24(15), 6710–6718 (2004).
  • Mondesire WH, Jian W, Zhang H et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10(20), 7031–7042 (2004).
  • Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102(2), 292–299 (2006).
  • Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM, Zhang Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr. Relat. Cancer 13(3), 863–873 (2006).
  • Boulay A, Rudloff J, Ye J et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 11(14), 5319–5328 (2005).
  • Zhu Y, Zhang X, Liu Y et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol. 33(5), 1349–1362 (2012).
  • García-García C, Ibrahim YH, Serra V et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18(9), 2603–2612 (2012).
  • Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol. 18(8), 1323–1328 (2007).
  • Kim D, Chung J. Akt: versatile mediator of cell survival and beyond. J. Biochem. Mol. Biol. 35(1), 106–115 (2002).
  • Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27(16), 2630–2637 (2009).
  • Carpenter JT, Roche H, Campone M et al. Randomized 3-arm, Phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23(Suppl. 16), Abstract 564 (2005).
  • Chow LWC, Sun Y, Jassem J et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Presented at: 29th Annual San Antonio Breast Cancer Conference. San Antonio, TX, USA, 14–17 December 2006 (Abstract 6091).
  • Bachelot T, Bourgier C, Cropet C et al. Randomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. J. Clin. Oncol. 30(22), 2718–2724 (2012).
  • Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520–529 (2012).
  • Hortobagyi GN, Piccart M, Rugo H et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 Phase III trial. Presented at: 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 6–10 December 2011 (Abstract S3-7).
  • Piccart M, Noguchi S, Pritchard KI et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 Phase III trial. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2012 (Abstract 559).
  • Bhattacharyya GS, Biswas J, Singh JK et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. Eur. J. Cancer 47, Abstract 16LBA (2011).
  • Gajria D, King T, Pannu H et al. Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: a Phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer. Presented at: 34th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 4–8 December 2011 (Abstract PD09-08).
  • Jerusalem G, Fasolo A, Dieras V et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res. Treat. 125(2), 447–455 (2011).
  • Morrow PK, Wulf GM, Ensor J et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 29(23), 3126–3132 (2011).
  • Andre F, Campone M, O’Regan R et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J. Clin. Oncol. 28(34), 5110–5115 (2010).
  • Hurvitz S, Andre F, Burris H et al. BOLERO-1: a randomized, Phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC). Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2012 (Abstract TPS648).
  • Alexander W. Meeting Highlights: San Antonio Breast Cancer Symposium. P.T. 36(3), 156–158 (2011).
  • Gnant M, Hortobagyi G, Rugo HS et al. Everolimus added to exemestane reduced bone turnover marker levels and disease progression in bone in postmenopausal women with advanced breast cancer: updated results from the BOLERO-2 trial. Presented at: 8th European Breast Cancer Conference. Vienna, Austria, 21–24 March 2012 (Abstract 3LBA).
  • Buckner JC, Forouzesh B, Erlichman C et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest. New Drugs 28(3), 334–342 (2010).
  • Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1603–1610 (2008).
  • Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur. J. Cancer 48(3), 340–346 (2012).
  • Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47(9), 1287–1298 (2011).
  • Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J. Natl. Cancer Inst. 104(2), 93–113 (2012).
  • Albiges L, Chamming’s F, Duclos B et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann. Oncol. 23(8), 1943–1953 (2012).
  • European Medicines Agency. Summary of opinion (post authorisation: Afinitor). 21 June 2012.
  • Hurvitz SA, Hu Y, O’Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat. Rev. doi:10.1016/j.ctrv.2012.04.008 (2012) (Epub ahead of print).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.